Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy
- 308 Downloads
Background Advances in the treatment of HIV infection have enabled better control of the disease, allowing patients to enjoy a longer life expectancy. However, the ageing of patients leads to an increased prevalence of cardiovascular disease. Various studies have found that pharmaceutical care results in better control of cardiovascular risk factors. Objective To measure the impact of pharmaceutical care on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy. Setting Outpatient pharmacy service of a tertiary hospital, Spain. Methods A pre/post-intervention quasi-experimental clinical study was conducted in which health education and pharmacist interventions to reduce cardiovascular risk factors were carried out in a single patient cohort using the Dader method of pharmacotherapy, with a 12-month follow-up period per patient. Patients included were older than 50 years, with moderate/elevated cardiovascular risk. Data were obtained from patient clinical histories, dispensing records and patient interviews, and were subjected to statistical analysis. Main outcome measure Cardiovascular risk estimated by SCORE and REGICOR equations. Results Forty-two patients completed the study. Of these, 93 % were men, with an average age of 57 years and 15 years since diagnosis of HIV. A reduction was observed in the mean values (baseline vs. 12 months) of the following cardiovascular risk factors: systolic blood pressure (P = 0.009), diastolic blood pressure (P = 0.010), total cholesterol (P = 0.006), low-density lipoprotein cholesterol (LDL-c; P = 0.039), triglycerides (P = 0.010) and total cholesterol/high-density lipoprotein cholesterol (HDL-c; P < 0.001). An increase in HDL-c (P = 0.037) was also observed. The average cardiovascular risk estimated by the SCORE instrument was reduced from 7.6 % at the beginning of the study to 6.4 % after 12 months (P = 0.039). The risk estimate according to REGICOR also decreased (P = 0.002). Over the 12-month period, 6.3 ± 3.4 interventions were carried out per patient. Quantitative ineffectiveness was the most prevalent negative outcome associated with medication throughout the study, and noncompliance was the most frequent cause. Interventions on health education were the most common, followed by interventions on improving adherence. Conclusion Pharmaceutical care, delivered as a combination of health education and pharmacotherapy follow-up to outpatients at a tertiary hospital, had a positive impact on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy.
KeywordsHIV Older patients Pharmaceutical care Pharmacotherapy follow-up Spain
This article is part of the doctoral thesis of Elza Domingues within the Doctoral Programme in Clinical Medicine and Public Health, Granada University, Spain. We acknowledge support from the Coordination for the Improvement of Higher Education Personnel (CAPES) Foundation, Brazil; the staff of the Virgen de las Nieves University Hospital, Spain; and Manuela Expósito Ruiz, FIBAO (Biohealth Research Foundation of Eastern Andalusia), Spain, for statistical analysis.
Research presented here was supported by funding from the CAPES Foundation, Brazil, process no. 0675/13-0.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 2.United Nations Programme on HIV/AIDS. HIV and aging: a special supplement to the UNAIDS report on the global AIDS epidemic 2013 (2013). http://www.unaids.org/sites/default/files/media_asset/20131101_JC2563_hiv-and-aging_en_0.pdf. Accessed 10 June 2016.
- 3.Diez M, Diaz A, Garriga C, Pons M, Ten A, Marcos H, et al. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. Euro Surveill. 2014; 19(20). doi: 10.2807/1560-7917.ES2014.19.20.20805.
- 5.Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010398/epdf. Accessed 10 June 2016.
- 9.Sabater Hernandez D, Silva Castro MM, Faus Dader MJ. Dader method. Medication review with follow-up guidelines. 3rd ed. Granada: Pharmaceutical Care Research Group; 2007 (Spanish).Google Scholar
- 13.Aboud M, Elgalib A, Pomeroy L, Panayiotakopoulos G, Skopelitis E, Kulasegaram R, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. Int J Clin Pract. 2010;64(9):1252–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Torres-Degayón V, Torres-Murillo JM, Baena-Parejo MI, Muñoz-Villanueva MC, Montes-Redondo G, Calleja-Hernández MA, et al. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department. J Clin Pharm Ther. 2015;40(4):452–60.CrossRefPubMedGoogle Scholar
- 22.Jódar-Sánchez F, Malet-Larrea A, Martín JJ, García-Mochón L, López Del Amo MP, Martínez-Martínez F, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33(6):599–610.CrossRefPubMedGoogle Scholar
- 23.Amariles P, Sabater-Hernández D, García-Jiménez E, Rodriguez-Chamorro MA, Prats-Más R, Marin-Magán F, et al. Effectiveness of Dader Method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial. J Manag Care Pharm. 2012;18(4):311–23.PubMedGoogle Scholar